{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:24:09Z","timestamp":1793363049408,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2023-PT320-07"],"award-info":[{"award-number":["2023-PT320-07"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-03951-5","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T16:57:19Z","timestamp":1736614639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhiliang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rula","family":"Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"3951_CR1","doi-asserted-by":"crossref","unstructured":"Fernando SC, Polkinghorne KR, Lim WH, Mulley WR. Early Versus Late Acute Amr in Kidney Transplant Recipients-a Comparison of Treatment Approaches and Outcomes from the Anzdata Registry. Transplantation (2023) 107(11):2424-32.","DOI":"10.1097\/TP.0000000000004700"},{"issue":"3","key":"3951_CR2","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/TP.0000000000003274","volume":"105","author":"W Irish","year":"2021","unstructured":"Irish W, Nickerson P, Astor BC, Chong E, Wiebe C, Moreso F, et al. Change in estimated gfr and risk of allograft failure in patients diagnosed with late active antibody-mediated rejection following kidney transplantation. Transplantation. 2021;105(3):648\u201359.","journal-title":"Transplantation"},{"issue":"11","key":"3951_CR3","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1097\/TP.0000000000003145","volume":"104","author":"AB Lichvar","year":"2020","unstructured":"Lichvar AB, Tremblay S, Leino AD, Shields AR, Cardi MA, Abu Jawdeh BG, et al. Reducing donor-specific antibody during Acute rejection diminishes long-term renal allograft loss: comparison of early and late rejection. Transplantation. 2020;104(11):2403\u201314.","journal-title":"Transplantation"},{"issue":"8","key":"3951_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/tri.13436","volume":"32","author":"GA Bohmig","year":"2019","unstructured":"Bohmig GA, Eskandary F, Doberer K, Halloran PF. The therapeutic challenge of late antibody-mediated kidney allograft rejection. Transpl Int. 2019;32(8):775\u201388.","journal-title":"Transpl Int"},{"issue":"12","key":"3951_CR5","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1056\/NEJMra1802677","volume":"379","author":"A Loupy","year":"2018","unstructured":"Loupy A, Lefaucheur C. Antibody-mediated rejection of Solid-Organ Allografts. N Engl J Med. 2018;379(12):1150\u201360.","journal-title":"N Engl J Med"},{"key":"3951_CR6","doi-asserted-by":"crossref","unstructured":"Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S et al. Recommended Treatment for Antibody-Mediated Rejection after Kidney Transplantation: The 2019 Expert Consensus from the Transplantion Society Working Group. Transplantation (2020) 104(5):911\u2009\u2013\u200922.","DOI":"10.1097\/TP.0000000000003095"},{"issue":"13","key":"3951_CR7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting Cd38 with Daratumumab Monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207\u201319.","journal-title":"N Engl J Med"},{"issue":"10027","key":"3951_CR8","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab Monotherapy in patients with treatment-refractory multiple myeloma (Sirius): an Open-Label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551\u201360.","journal-title":"Lancet"},{"key":"3951_CR9","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","volume":"9","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Usmani SZ. Cd38 antibodies in multiple myeloma: mechanisms of Action and modes of Resistance. Front Immunol. 2018;9:2134.","journal-title":"Front Immunol"},{"issue":"12","key":"3951_CR10","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/j.ajt.2023.06.018","volume":"23","author":"T de Nattes","year":"2023","unstructured":"de Nattes T, Kaveri R, Farce F, Francois A, Guerrot D, Hanoy M, et al. Daratumumab for antibody-mediated rejection: is it time to Target the Real Culprit? Am J Transpl. 2023;23(12):1990\u20134.","journal-title":"Am J Transpl"},{"key":"3951_CR11","doi-asserted-by":"crossref","unstructured":"Doberer K, Klager J, Gualdoni GA, Mayer KA, Eskandary F, Farkash EA et al. Cd38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-Mediated Kidney Allograft Rejection. Transplantation (2021) 105(2):451-7.","DOI":"10.1097\/TP.0000000000003247"},{"issue":"7","key":"3951_CR12","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1681\/ASN.2018121254","volume":"30","author":"J Kwun","year":"2019","unstructured":"Kwun J, Matignon M, Manook M, Guendouz S, Audard V, Kheav D, et al. Daratumumab in sensitized kidney transplantation: potentials and limitations of Experimental and Clinical Use. J Am Soc Nephrol. 2019;30(7):1206\u201319.","journal-title":"J Am Soc Nephrol"},{"key":"3951_CR13","doi-asserted-by":"publisher","first-page":"1087597","DOI":"10.3389\/fimmu.2022.1087597","volume":"13","author":"L Zhu","year":"2022","unstructured":"Zhu L, Guo Z, Zhao D, Sa R, Zhao G, Guo H, et al. Case Report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of De Novo Donor-Specific antibodies. Front Immunol. 2022;13:1087597.","journal-title":"Front Immunol"},{"key":"3951_CR14","doi-asserted-by":"publisher","first-page":"839380","DOI":"10.3389\/fimmu.2022.839380","volume":"13","author":"L Cabezas","year":"2022","unstructured":"Cabezas L, Jouve T, Malvezzi P, Janbon B, Giovannini D, Rostaing L, et al. Tocilizumab and active antibody-mediated rejection in kidney transplantation: a Literature Review. Front Immunol. 2022;13:839380.","journal-title":"Front Immunol"},{"issue":"Suppl 4","key":"3951_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ajt.17207","volume":"22","author":"SC Jordan","year":"2022","unstructured":"Jordan SC, Ammerman N, Huang E, Vo A. Importance of Il-6 inhibition in Prevention and treatment of antibody-mediated rejection in kidney allografts. Am J Transpl. 2022;22(Suppl 4):28\u201337.","journal-title":"Am J Transpl"},{"issue":"9","key":"3951_CR16","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1111\/ajt.14228","volume":"17","author":"J Choi","year":"2017","unstructured":"Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, et al. Assessment of Tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in hla-sensitized renal allograft recipients. Am J Transpl. 2017;17(9):2381\u20139.","journal-title":"Am J Transpl"},{"issue":"1","key":"3951_CR17","doi-asserted-by":"publisher","first-page":"e14853","DOI":"10.1111\/ctr.14853","volume":"37","author":"P Khairallah","year":"2023","unstructured":"Khairallah P, Robbins-Juarez S, Patel S, Shah V, Toma K, Fernandez H, et al. Tocilizumab for the Treatment of Chronic Antibody Mediated Rejection in kidney transplant recipients. Clin Transpl. 2023;37(1):e14853.","journal-title":"Clin Transpl"},{"issue":"4","key":"3951_CR18","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/TP.0000000000002895","volume":"104","author":"BH Shin","year":"2020","unstructured":"Shin BH, Everly MJ, Zhang H, Choi J, Vo A, Zhang X, et al. Impact of Tocilizumab (Anti-Il-6r) treatment on immunoglobulins and Anti-hla Antibodies in kidney transplant patients with chronic antibody-mediated rejection. Transplantation. 2020;104(4):856\u201363.","journal-title":"Transplantation"},{"key":"3951_CR19","doi-asserted-by":"publisher","first-page":"661614","DOI":"10.3389\/fimmu.2021.661614","volume":"12","author":"L Zhu","year":"2021","unstructured":"Zhu L, Guo Z, Sa R, Guo H, Li J, Chen G. Case Report: splenic irradiation for the treatment of chronic active antibody-mediated rejection in kidney allograft recipients with De Novo Donor-Specific Antibodies. Front Immunol. 2021;12:661614.","journal-title":"Front Immunol"},{"issue":"9","key":"3951_CR20","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/ajt.15898","volume":"20","author":"A Loupy","year":"2020","unstructured":"Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, et al. The Banff 2019 kidney Meeting Report (I): updates on and clarification of Criteria for T Cell- and antibody-mediated rejection. Am J Transpl. 2020;20(9):2318\u201331.","journal-title":"Am J Transpl"},{"issue":"3","key":"3951_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000503951","volume":"9","author":"D Spica","year":"2019","unstructured":"Spica D, Junker T, Dickenmann M, Schaub S, Steiger J, Rufli T, et al. Daratumumab for treatment of antibody-mediated rejection after abo-incompatible kidney transplantation. Case Rep Nephrol Dial. 2019;9(3):149\u201357.","journal-title":"Case Rep Nephrol Dial"},{"key":"3951_CR22","doi-asserted-by":"publisher","first-page":"11771","DOI":"10.3389\/ti.2023.11771","volume":"36","author":"D Zhao","year":"2023","unstructured":"Zhao D, Guo Z, Zhao G, Sa R, Zhu L, Chen G. A Novel Daratumumab-based regimen for desensitization in highly hla-presensitized patients awaiting kidney transplantation. Transpl Int. 2023;36:11771.","journal-title":"Transpl Int"},{"key":"3951_CR23","doi-asserted-by":"crossref","unstructured":"Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S et al. A randomized phase 2 trial of Felzartamab in antibody-mediated rejection. N Engl J Med (2024).","DOI":"10.1056\/NEJMoa2400763"},{"issue":"8","key":"3951_CR24","doi-asserted-by":"publisher","first-page":"e13908","DOI":"10.1111\/ctr.13908","volume":"34","author":"A Lavacca","year":"2020","unstructured":"Lavacca A, Presta R, Gai C, Mella A, Gallo E, Camussi G, et al. Early effects of First-Line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation. Clin Transpl. 2020;34(8):e13908.","journal-title":"Clin Transpl"},{"issue":"5","key":"3951_CR25","doi-asserted-by":"publisher","first-page":"e14936","DOI":"10.1111\/ctr.14936","volume":"37","author":"B Boonpheng","year":"2023","unstructured":"Boonpheng B, De Castro ICC, Ng YH, Blosser C, Bakthavatsalam R, Gimferrer I, et al. Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients. Clin Transpl. 2023;37(5):e14936.","journal-title":"Clin Transpl"},{"issue":"8","key":"3951_CR26","doi-asserted-by":"publisher","first-page":"e14734","DOI":"10.1111\/ctr.14734","volume":"36","author":"M Pearl","year":"2022","unstructured":"Pearl M, Weng PL, Chen L, Dokras A, Pizzo H, Garrison J, et al. Long Term Tolerability and Clinical outcomes Associated with Tocilizumab in the treatment of refractory antibody mediated rejection (Amr) in Pediatric Renal Transplant recipients. Clin Transpl. 2022;36(8):e14734.","journal-title":"Clin Transpl"},{"issue":"4","key":"3951_CR27","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1097\/TXD.0000000000000988","volume":"6","author":"AA Pottebaum","year":"2020","unstructured":"Pottebaum AA, Venkatachalam K, Liu C, Brennan DC, Murad H, Malone AF, et al. Efficacy and safety of Tocilizumab in the treatment of Acute active antibody-mediated rejection in kidney transplant recipients. Transpl Direct. 2020;6(4):e543.","journal-title":"Transpl Direct"},{"issue":"5","key":"3951_CR28","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1053\/j.ajkd.2022.11.010","volume":"81","author":"RE Scalzo","year":"2023","unstructured":"Scalzo RE, Sanoff SL, Rege AS, Kwun J, Knechtle SJ, Barisoni L, et al. Daratumumab Use prior to kidney transplant and T cell-mediated rejection: a Case Report. Am J Kidney Dis. 2023;81(5):616\u201320.","journal-title":"Am J Kidney Dis"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-03951-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-03951-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-03951-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T17:03:04Z","timestamp":1736614984000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-03951-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3951"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-03951-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Tongji Hospital, Wuhan, China (TJ-IRB20230729). All patients provided written informed consent before study inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}